multiple-myeloma

Documents about multiple-myeloma

• This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.#832794ClinicalTrials.gov
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery#856416ClinicalTrials.gov
• A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma#860448ClinicalTrials.gov
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)#888284ClinicalTrials.gov
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma#850409ClinicalTrials.gov
• Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma#860814ClinicalTrials.gov
• Cognitive Speed–Accuracy Dissociation in Multiple Myeloma: A Cross‑Sectional Study#4943Europe PMC
• Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy#143620ClinicalTrials.gov
• Differential RNA splicing as a potentially important driver mechanism in multiple myeloma#242867Ora Oxford University Research
• Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM#249612ClinicalTrials.gov
• Practical recommendations for infectious prophylaxis and vaccination in multiple myeloma patients.#371396NCBI PubMed Central
• A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel#837188ClinicalTrials.gov
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM#852059ClinicalTrials.gov
• A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.#805713ClinicalTrials.gov
• A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma#811473ClinicalTrials.gov
• Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia#836844ClinicalTrials.gov
• A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma#857373ClinicalTrials.gov
• MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation#901767ClinicalTrials.gov
• Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma#860698ClinicalTrials.gov
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)#897506ClinicalTrials.gov
• Monoallelic deletion of BCMA is a frequent feature in multiple myeloma#121906HAL (France)
• Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth#126856HAL (France)
• Prevalence Of Metabolic Comorbidities And Viral Infections In Monoclonal Gammopathy#167478EliScholar
• Inflammatory bone marrow microenvironment impairs the therapeutic effect of daratumumab-lenalidomide in multiple myeloma#676986HAL (France)
• Phase I Study of Sequential Cord Blood Transplants#862228ClinicalTrials.gov
• Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide#872614ClinicalTrials.gov
• Efficacy of a Patient Education Video#875008ClinicalTrials.gov
• Telehealth-based Symptom Management for Veterans Treated With Selinexor#881746ClinicalTrials.gov
• Detection and Pathogenesis of Novel Protein F#890947ClinicalTrials.gov
• A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan#907452ClinicalTrials.gov
• Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM#849299ClinicalTrials.gov
• High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment#892612ClinicalTrials.gov
• A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM#914346ClinicalTrials.gov
• Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma#966576ClinicalTrials.gov
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma#839549ClinicalTrials.gov
• A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)#862944ClinicalTrials.gov
• STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS#902187ClinicalTrials.gov
• Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT#981212ClinicalTrials.gov
• Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)#861347ClinicalTrials.gov
• Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).#885339ClinicalTrials.gov
• PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.#268106ClinicalTrials.gov
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma#851901ClinicalTrials.gov
• A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma#892560ClinicalTrials.gov
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer#882538ClinicalTrials.gov
• Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020#195820HAL (France)
• Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article#195822HAL (France)
• Identification and validation of prognostic genes related to centrosome amplification in multiple myeloma.#269515NCBI PubMed Central
• Single-nuclei UPR profiling by flow cytometry reveals bortezomib resistance mechanisms in multiple myeloma#326276HAL (France)
• EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway#379314Spiral
• Romosozumab Safely Restores Bone Mass in Multiple Myeloma via Osteoblast Reprogramming: A Phase IIa Study#424134bioRxiv / medRxiv